Prescription drugs and subtype-specific breast cancer risk

Project number: 
15-192
Approval date: 
Friday, January 29, 2016
Principal Investigator: 
Bakos,Brendan
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Not Available
Datasets requested: 
bc cancer-external
Consolidation registry (Ministry of Health)
bc cancer
PharmaNet
Research objective: 

Primary Objectives
1. Evaluate the association between cumulative bisphosphonate use (>5 years) and the risk of breast cancer and breast cancer subtypes.
2. Evaluate the association between omeprazole use and the risk of breast cancer and breast cancer subtypes.

Secondary Objectives
1. Explore the association between several classes of pharmaceuticals, including anti-depressants and statins, and overall and subtype specific breast cancer risk.
2. Examine the modifying effect of single nucleotide polymorphisms (SNPs) on the association between bisphosphonates and omeprazole and the risk of breast cancer.

Hypotheses
Use of bisphosphonates and omeprazole will reduce the risk of breast cancer.


Page last revised: December 5, 2017